Healthcare Scan

Scan

Healthcare Scan

Scan symbols 19
UNHCVSLLYMRNABIIBVRTXMDTJNJPFEMRKAMGNGILDTMOVEEVDXCMSYKABTISRGZTS
Watchlists 1
@healthcare
raw scan snapshot — prices as of scan date, not live 38 rows · screens, not recommendations

Healthcare stays sharply bifurcated: managed care (UNH +42.6% 3M, CVS +38% 3M) and GLP-1/mRNA pharma (LLY +20.9% 3M, MRNA +15.2% 30D) lead while legacy medtech (ISRG, ABT, SYK) and animal health (ZTS) stay in collapse. The split is structural, not noise — insurers + biopharma winning, focused devices losing. Large-cap pharma anchors (JNJ/MRK/AMGN) softened this week.

Source: healthcare.json. Latest bar Thursday 2026-06-18; some names 06-16/06-17 (stale) flagged inline.

Quick Snapshot

Signal Reading
Overall 🟡 Sector divided by sub-sector — managed care (UNH/CVS) + GLP-1/mRNA pharma (LLY/MRNA) advancing while devices (ISRG/ABT/SYK) and animal health (ZTS) in structural decline. Favor pharma/insurer, exit focused devices
Leaders UNH ($407.65, RSI 67, +42.6% 3M, -2% from ATH), MRNA (RSI 64, +15.2% 30D, +42.7% vs SMA200), CVS (RSI 61, +38% 3M, -4.3% from ATH), LLY (RSI 60, +20.9% 3M)
Laggards ZTS (RSI 38, -32.1% 3M, -51.7% from ATH, collapse), ABT (RSI 47, -17% 3M, -36.4% from ATH, collapse), GILD (RSI 40, -11.7% 3M), ISRG (RSI 40, -15.2% 3M, collapse), VEEV (RSI 46, -47.4% from ATH, collapse)
Key insight UNH (+42.6% 3M) + CVS (+38% 3M) both near ATH while ISRG/ABT/ZTS all in collapse regime — the insurer/managed-care re-rate is the dominant sector signal; focused medtech is the structural loser

Price Table

Stock Price RSI vs SMA20 7D% 30D% 3M% 52wkHi% Signal
ZTS $78.71 38.3 ↓ -0.7% -2.05% -1.70% -32.14% -51.73% ❌ Don't Buy (collapse)
ISRG $406.78 40.3 ↓ -2.8% -2.17% -7.88% -15.24% -32.64% ❌ Don't Buy (collapse)
GILD $123.76 40.4 ↓ -3.4% -0.51% -4.54% -11.72% -21.32% 🔍 Watch
JNJ $228.39 45.2 -1.4% -3.67% -0.13% -3.32% -9.26% 🔒 Hold
VEEV $163.38 46.3 ↓ -2.4% -5.03% -0.29% -12.49% -47.38% ❌ Don't Buy (collapse, 06-16, 2d stale)
TMO $464.61 46.6 -1.7% -2.60% +3.39% -1.19% -26.61% 🔍 Watch
AMGN $337.60 47.0 -1.1% -5.25% +2.07% -2.79% -13.72% 🔒 Hold
MRK $113.87 47.4 -2.8% -3.53% +0.40% +0.11% -9.01% 🔍 Watch
ABT $88.41 47.5 0.0% +0.25% -0.46% -17.00% -36.42% 🔍 Watch (collapse)
DXCM $71.23 50.3 -3.0% -2.86% +6.39% +5.89% -19.46% 🔒 Hold (06-17)
SYK $310.58 51.5 +0.9% -0.58% -0.84% -10.80% -23.29% 🔍 Watch (06-16, 2d stale)
PFE $25.21 51.9 -2.5% +1.36% -1.75% -3.56% -12.31% 🔍 Watch
BIIB $198.67 55.2 +1.9% -0.78% +4.26% +8.32% -4.56% 🔒 Hold (06-17)
MDT $81.32 57.0 +3.5% -2.18% +5.17% -7.30% -23.52% 🔍 Watch (06-16, 2d stale)
VRTX $453.17 58.6 +3.0% +1.56% +3.80% -2.02% -10.78% 🔒 Hold (06-16, 2d stale)
LLY $1,098.57 60.3 -0.1% -2.63% +7.55% +20.86% -7.12% 🔒 Hold
CVS $98.32 61.3 +3.0% -1.82% +4.40% +38.03% -4.33% ⚠️ Approaching OB
MRNA $55.40 64.4 +14.8% +10.58% +15.15% +2.73% -6.97% 📈 Accumulate (06-16, 2d stale)
UNH $407.65 66.5 +4.3% -0.13% +4.82% +42.56% -2.00% 🔒 Hold (06-16, 2d stale)

Tier Analysis

Oversold / Collapsing (RSI < 45)

  • ZTS ($78.71, RSI 38) — Zoetis: animal health in structural collapse, -32.1% 3M, -51.7% from ATH, death-cross, -34.8% vs SMA200. Worst name in the scan; no reversal. Do not buy.
  • ISRG ($406.78, RSI 40) — Intuitive Surgical: collapse regime, -15.2% 3M, -32.6% from ATH, death-cross, -17.1% vs SMA200. Surgical robotics de-rating on competition (J&J Ottava, Medtronic Hugo). thesis: intact per engine but trend is broken. No entry.
  • GILD ($123.76, RSI 40) — Gilead: pullback, -11.7% 3M, -21% from ATH. Golden cross intact; watch for RSI < 40 capitulation entry.

Neutral / Basing (RSI 45–60)

  • JNJ ($228.39, RSI 45) — J&J: basing, golden cross, +6.9% vs SMA200, -9.3% from ATH. Softened this week (-3.67% 7D) but diversified-pharma thesis intact post-Kenvue spin. Hold.
  • VEEV ($163.38, RSI 46) — Veeva: collapse regime, -47.4% from ATH, death-cross, -25.5% vs SMA200. Healthcare-SaaS multiple still compressing. Avoid. (06-16, 2d stale)
  • TMO ($464.61, RSI 47) — Thermo Fisher: pullback, -26.6% from ATH, death-cross. User-owned name; thesis: intact. Lab-tools basing. Watch.
  • AMGN ($337.60, RSI 47) — Amgen: basing, golden cross, +3% vs SMA200, -13.7% from ATH. Stable but soft (-5.25% 7D). Hold.
  • MRK ($113.87, RSI 47) — Merck: basing, golden cross, +10% vs SMA200, -9% from ATH. Keytruda franchise; pullback opportunity, watch.
  • ABT ($88.41, RSI 47) — Abbott: collapse regime, -17% 3M, -36.4% from ATH, death-cross, -21.5% vs SMA200. Libre CGM thesis challenged. Weak.
  • DXCM ($71.23, RSI 50) — Dexcom: pullback, +6.4% 30D, +5.5% vs SMA200, golden-cross broken (death-cross flag) but reclaiming SMA50. CGM name; hold. (06-17)
  • SYK ($310.58, RSI 51) — Stryker: downtrend, -10.8% 3M, -23.3% from ATH, death-cross. Ortho/medtech weak. Watch. (06-16, 2d stale)
  • PFE ($25.21, RSI 52) — Pfizer: basing, golden cross, flat vs SMA200, -12.3% from ATH. Post-COVID pipeline diversification. No urgency.
  • BIIB ($198.67, RSI 55) — Biogen: strong-up, golden cross, +13.9% vs SMA200, -4.6% from ATH. Alzheimer's franchise re-rating. Hold. (06-17)
  • MDT ($81.32, RSI 57) — Medtronic: weak-up reclaiming SMA20, but death-cross and -23.5% from ATH. thesis: intact. Watch. (06-16, 2d stale)
  • VRTX ($453.17, RSI 59) — Vertex: basing, +3.8% 30D, -10.8% from ATH. CF + pipeline. Hold. (06-16, 2d stale)

Momentum / Leading (RSI 60–67)

  • LLY ($1,098.57, RSI 60) — Eli Lilly: GLP-1 oligopoly, strong-up, golden cross, +20.9% 3M, +14.5% vs SMA200, -7% from ATH. The sector's premier compounder. Hold.
  • CVS ($98.32, RSI 61) — CVS Health: strong-up, golden cross, +38% 3M, +24% vs SMA200, near ATH (-4.3%). Pharmacy→insurance re-rate; RSI 61 approaching extended. Don't chase, hold if owned.
  • MRNA ($55.40, RSI 64) — Moderna: strong-up, golden cross, +15.2% 30D, +42.7% vs SMA200, +113.9% 1Y, -7% from ATH. mRNA re-rating confirmed across biotech + healthcare scans. Best momentum name. (06-16, 2d stale)
  • UNH ($407.65, RSI 67) — UnitedHealth: strong-up, golden cross, +42.6% 3M, +24.2% vs SMA200, near ATH (-2%). Managed-care recovery thesis; strongest large-cap run in the scan. Hold. (06-16, 2d stale)

Entry Zones

Stock Price Zone RSI 30D% Setup
LLY $1,098.57 <$1,080 60.3 +7.6% GLP-1 oligopoly; near ATH; GC; accumulate on any dip
MRNA $55.40 <$58 64.4 +15.2% mRNA re-rating; +42.7% vs SMA200; momentum early innings; GC
MRK $113.87 <$112 47.4 +0.4% Keytruda franchise; -9% from ATH; GC; +10% vs SMA200; pullback entry
JNJ $228.39 <$225 45.2 -0.1% Diversified pharma; GC; -9% from ATH; soft week = core add
GILD $123.76 <$120 40.4 -4.5% HIV antivirals; -21% from ATH; GC intact; watch RSI < 40 capitulation

Action Matrix

Action Stocks Why
🔒 HOLD LLY, UNH, JNJ, AMGN, BIIB, VRTX, DXCM Trends/theses intact; insurers + biopharma anchors; don't sell into strength
📈 ACCUMULATE MRNA mRNA platform re-rating; +10.6% 7D; golden cross; -7% from ATH = still early
🔍 WATCH GILD, MRK, TMO, PFE, MDT, SYK, ABT Pullbacks with intact-ish theses; wait for RSI confirmation or catalyst
⚠️ APPROACHING OVERBOUGHT CVS RSI 61, near ATH, +38% 3M — don't chase; wait for pullback
❌ DON'T BUY ZTS, ISRG, VEEV, ABT Collapse regime + death-cross; structural declines not finished

What Changed

  • UNH +42.6% 3M sustained — UnitedHealth's multi-month managed-care recovery holds (RSI 67, near ATH); DOJ-scrutiny fears faded, Medicare Advantage stable.
  • CVS +38% 3M, RSI 61 — CVS pharmacy→insurance transformation re-rating; near ATH (-4.3%), +24% vs SMA200. Approaching extended.
  • MRNA dual-scan confirmation — mRNA re-rating shows in both healthcare and biotech scans; +113.9% 1Y, +42.7% vs SMA200. Most significant sector inflection.
  • ZTS -32.1% 3M collapse — Zoetis remains the worst name; -51.7% from ATH, no reversal.
  • ISRG collapse deepens — Intuitive Surgical now -15.2% 3M, -32.6% from ATH, collapse regime. Engine still flags thesis: intact but the trend is structurally broken (device competition).
  • ABT into collapse — Abbott -17% 3M, -36.4% from ATH, collapse regime; Libre CGM thesis challenged.
  • Large-cap pharma softened — JNJ (-3.67% 7D, RSI 45), MRK (-3.53% 7D), AMGN (-5.25% 7D) all pulled back this week; anchors digesting, theses intact.

Key Discoveries

Discovery Implication
UNH + CVS both near ATH vs ISRG + ABT + ZTS all in collapse Healthcare sub-sector rotation: insurers winning, focused device-makers losing
MRNA confirmed across healthcare + biotech scans Dual-scan confirmation = mRNA re-rating is sector-wide, not single-scan noise
JNJ near-flat while ISRG/ABT/SYK down 11-32% 3M Diversified pharma outperforming focused medtech in this tape

Mistakes (Don't Repeat)

Mistake Lesson
Treating ISRG `thesis: intact` as a buy signal Engine thesis-tag ≠ trend; collapse regime + death-cross + device competition = no entry despite the tag
Chasing ZTS as an animal-health defensive Animal health carries idiosyncratic disease risk; not a true defensive (-52% from ATH proves it)

Open Questions

  • Is UNH's +42.6% 3M recovery complete, or does it run into Medicare Advantage enrollment season?
  • ISRG thesis: intact vs collapse regime — does the device franchise re-accelerate, or is the competitive de-rate structural?
  • ABT vs DXCM both CGM-exposed — is the continuous-glucose-monitor market oversupplied, or just ABT-specific weakness (DXCM is +6.4% 30D)?
10 events
DateTypeEvent
Jun 16 ScanHealthcare Scan Jun 25 ScanHealthcare Scan Jun 26 ScanHealthcare Scan Jul 11 ScanHealthcare Scan May 29 ScanHealthcare Scan Jul 7 ScanHealthcare Scan Jul 17 ScanHealthcare Scan Jul 25 ScanHealthcare Scan Jul 28 ScanHealthcare Scan Jul 31 ScanHealthcare Scan

No direct external sources are attached to this read.